The results of holmium laser resection of the prostate.

OBJECTIVE: To assess the results of holmium-laser resection of the prostate (HOLRP) in the treatment of benign prostatic hyperplasia. PATIENTS AND METHODS: Between 1994 and 1997, 967 patients underwent HOLRP in Tauranga, New Zealand, and in Derby, United Kingdom. The patients were followed at 1, 3 and 6 months after treatment using measurements of symptom score and urinary flow rate. RESULTS: There was a large and sustained improvement in symptom scores and urinary flow rates, with no mortality and low morbidity. CONCLUSION: We recommend this technique as an alternative to transurethral resection in the surgical treatment of bladder outlet obstruction due to benign prostatic hypertrophy.

Holmium: YAG laser resection of prostate (HoLRP) for patients in urinary retention.

We examined the holmium:YAG (Ho:YAG) laser as a tool to perform acute resection of obstructing prostatic tissue in the subgroup of men with benign prostatic hyperplasia (BPH) who present in urinary retention. A total of 36 men presented in acute urinary retention requiring catheterization before undergoing Ho:YAG laser resection of the prostate (HoLRP). Their mean age was 67 years. The mean laser energy delivery was 102 kJ (range 42-315 kJ). The mean postoperative catheterization time was 1.5 days (range 1-8 days), and only 3 men required a catheter for more than 48 hours. There were no acute perioperative complications. Improvement in voiding was immediate and sustained through 6 months of follow-up. At 6 months, the mean peak urinary flow rate was 22.5 mL/sec, and the AUA Symptom Index Score was 5.7. A meatal stricture requiring dilation in one man represents the sole late complication observed in this series. Late recurrence of urinary retention has occurred in two men who had contributing medical problems, for an overall treatment failure rate of 5.6%. Thus, HoLRP represents an effective surgical therapy for patients with bladder outlet obstruction presenting in urinary retention. Morbidity is minimal compared with electrocautery resection, while the efficacy and immediacy of voiding improvement appear similar.

Holmium:YAG laser resection of the prostate: preliminary experience with the first 400 cases.

AIM: To report the development of the technique of laser resection of the prostate using the holmium:YAG (Ho:YAG) laser and to present preliminary results. METHODS: Four hundred and eleven patients underwent Ho:YAG laser resection of the prostate (HoLRP). Preoperative and postoperative symptom scores, and flow rates were assessed. A description of the technique and its development is presented. RESULTS: The mean American Urological Association (AUA) symptom score reduced from 23.6 to 4.9, and the mean peak urinary flow rate improved from 7.7 ml/s to 22.6 ml/s at 6 months postoperatively. The mean hospital stay was 1.3 days and complication rates were lower than those generally associated with electrosurgical transurethral resection of the prostate (TURP). CONCLUSION: Transurethral resection of the prostate using Ho:YAG laser produces early results equivalent to or better than those usually associated with electrosurgical TURP, with a shorter hospital stay and a lower rate of complications.

The use of the holmium laser in the treatment of benign prostatic hyperplasia.

The holmium wavelength (2.1 microns) can be used for incision, ablation, and resection of prostate tissue. Four different techniques for the surgical management of benign prostate hyperplasia (BPH) have evolved using the holmium laser either alone or in combination with Nd:YAG energy. The results in 650 patients undergoing these procedures are presented. The holmium laser has been used most recently to perform a transurethral resection of the prostate in 381 patients to date. This procedure appears to be the most efficient way of using the holmium laser for the removal of obstructing prostatic tissue.

Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia.

OBJECTIVES: To assess the early efficacy and safety of holmium laser resection of the prostate (HoLRP) for the treatment of patients with symptomatic benign prostatic hyperplasia (BPH). METHODS: The initial 84 patients undergoing HoLRP at this institution are reported. All patients underwent standard urologic evaluation for BPH with American Urological Association (AUA) symptom score, peak urinary flow rate (Qmax), ultrasound prostate volume estimation, prostate-specific antigen and digital rectal examination. The patients were reassessed at 1 month (72 patients) and 3 months (48 patients) postoperatively. The resection time, total operating time, holmium energy used (kilojoules), catheter time, and hospital stay were all recorded. RESULTS: The mean patient age was 65.3 years (49 to 80). The mean AUA score improved from 21.3 preoperatively to 7.6 at 1 month and 4.1 at 3 months. The mean Qmax likewise increased from 7.5 mL/s preoperatively to 17.8 mL/s at 1 month and 19.3 mL/s at 3 months. Two patients (2%) required bladder irrigation for heavy hematuria perioperatively and 4 patients (5%) required recatheterization. Few patients experienced irritative urinary symptoms and to only a mild degree. CONCLUSIONS: The technique of HoLRP produces a cavity identical in appearance to transurethral resection of the prostate. It is a relatively bloodless procedure that results in a short catheter time, immediate symptomatic improvement, and minimal postoperative irritative symptoms. The short-term results are excellent but longer-term follow-up is necessary.